Table 4.
Patient characteristics and outcome between those with advanced lung cancer inflammation index ALI score <18 (more inflammation) and those with ALI score > 18 (less inflammation) at the time of diagnosis
| Variable | ALI < 18 (n = 83) (%) | ALI ≥ 18 (n = 90) (%) | P = value |
|---|---|---|---|
|
Age (median) |
56 |
58 |
0.26 (a) |
|
Male |
57 (69) |
59 (65) |
0.74 (b) |
|
AA |
42 (51) |
48 (53) |
0.76 (b) |
|
Adenocarcinoma |
51 (61) |
53 (59) |
0.75 (b) |
|
PS 2-4 |
27 (32) |
15 (17) |
0.02 (b) |
|
No chemotherapy |
41 (49) |
18 (20) |
<0.001 (b) |
|
>2 metastatic sites |
48 (58) |
32 (35) |
0.003 (b) |
|
Response to chemotherapy |
15 (18%) |
50 (56%) |
<0.0001(b) |
|
Median PFS |
2.4 |
5.1 |
<0.001 (c) |
| Median OS | 3.4 | 8.3 | <0.001 (c) |
(a) Student t-test, (b) Chi-square test, (c) Log rant test, AA = African American, PS = Performance status, PFS = Progression free survival, OS = Overall survival. Significant results shown in bold.